大和:維持維亞生物(1873.HK)目標價10.9港元 評級“買入”
大和發表研究報告指,早前維亞生物(1873.HK)公佈有關收購SYNthesis全部股權該協議的最後截止日期延長至明年2月28日,該行表示,因預期財務報表將會延遲至明年三月才跟公司合併,對公司明年全年收入造成輕微影響,因其業務規模較小,故輕微下調明年公司收入預測0.9%,維持目標價10.9港元,重申“買入”評級。
大和認為,預期2019-2022年核心純利年複合增長預測將擴大至90%,現時股價未能完全反映朗華製藥整合於公司CRO平台所產生的協同效應,該行對公司的長遠發展較市場正面,亦認為其垂直收購戰略與藥明康德(2359.HK)相似,未來或成為合同開發與生產外包及受託研究機構行業的領先者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.